Avacta Group plc
Notification of Results
Avacta Group plc, the company providing innovative, high value technologies and
services to the pharmaceutical and diagnostics markets, will announce its
results for the year ended 31 July 2009, on Thursday 26 November.
An analyst presentation will take place at the offices of Daniel Stewart &
Company Plc, Becket House, 36 Old Jewry, London EC2R 8DD, on the day and those
wishing to attend should contact Kathy Boate at the details below.
4 November 2009
Enquiries:
Avacta Group plc Tel: 0870 835 4367
Alastair Smith, Chief Executive Officer www.avacta.com
Haggie Financial LLP Tel: 020 7417 8989
Kathy Boate/Nicholas Nelson Kathy.boate@haggie.co.uk
Nominated Adviser: Tel: 020 7776 6550
Daniel Stewart & Company Plc
Simon Leathers
Novum Securities Limited Tel: 020 7399 9400
Henry Turcan
Notes to Editors:
About Avacta
Avacta was spun-out from the University of Leeds in 2004 by its current
management team as a biophysics company, with the aim of combining the
disciplines of physics and biology to develop innovative technologies and
expert technical services to address unmet needs in the biopharmaceutical and
healthcare sectors. Avacta has a core bio-analytical technology development
programme addressing the needs of the biopharmaceutical sector to fully
characterise their new products at the earliest stage in their development to
reduce the risk of late stage failure. High end analytical instruments and
leading edge contract research services are being provided to the
biopharmaceutical and healthcare/personal-care materials sectors through the
Group's biotech support division, Avacta Analytical. High value solutions for
rapid, point of care diagnostics based on these core bio-analytical
technologies, with a near term focus on veterinary diagnostics, are being
delivered through Avacta Animal Health. Longer term these technologies will be
transferred into the human clinical diagnostics market. Avacta listed on AIM in
August 2006.